CJC-1295
By Chris Hallewell, Founder, Underground Biohacking
Last reviewed
Research use only. Not FDA-approved. Banned by WADA (S2.2 category).
CJC-1295 is a lab made copy of growth hormone releasing hormone. The version studied in people, CJC-1295 with DAC, sticks to blood albumin and keeps working for days. In healthy adults it raised growth hormone and IGF-1 for over a week. That is the whole human record: two small trials in the mid 2000s. Nobody has tested whether it builds muscle, burns fat or slows ageing in people. The version without DAC has no human trials at all.
What is CJC-1295?
CJC-1295 is a synthetic copy of growth hormone releasing hormone (GHRH). GHRH is the brain signal that tells your pituitary gland to release growth hormone. CJC-1295 copies the first 29 amino acids of GHRH, the shortest piece that still works. Four of those amino acids are swapped, so blood enzymes cannot chop it up as quickly. Two different drugs are sold under this name, and the difference matters. CJC-1295 with DAC carries a chemical hook called a drug affinity complex. The hook grabs albumin, the most common protein in your blood, and locks the peptide onto it. Riding on albumin, the peptide escapes the kidneys and keeps signalling for days. This is the form tested in the human trials. CJC-1295 without DAC has no hook. It is modified GRF 1-29, part of the same GHRH analogue family as the approved drug tesamorelin. It clears fast, so it gives a short burst of growth hormone rather than a steady lift. The two forms behave differently enough that evidence for one says little about the other.
What is CJC-1295 used for?
- In healthy adults, one injection of CJC-1295 with DAC raised blood growth hormone two to ten fold for six days or more.[1]Human study
- In the same adults, IGF-1, the growth signal that growth hormone switches on, rose 1.5 to 3 fold for nine to eleven days.[1]Human study
- In adults given repeat injections of the DAC form, average IGF-1 stayed above the starting level for up to 28 days.[1]Human study
- In healthy men, CJC-1295 with DAC lifted trough growth hormone 7.5 fold and IGF-1 by 45 percent.[2]Human study
- In those same men, the body's natural growth hormone pulses kept their normal timing and size.[2]Human study
- In rats, CJC-1295 produced four times the growth hormone output of the unmodified peptide over two hours.[3]Animal or lab study only
- In mice losing muscle to steroid drugs, CJC-1295 combined with ipamorelin improved the muscle's peak pulling force.[4]Animal or lab study only
How many units is your CJC-1295 dose?
Enter your vial, water and dose. Get the units to draw.
How does CJC-1295 work?
CJC-1295 is a synthetic copy of the active part of growth-hormone-releasing hormone, or GHRH. GHRH is the signal your hypothalamus sends to the pituitary gland. It tells the pituitary to make and release growth hormone. It comes in two forms. The DAC version carries a Drug Affinity Complex. That is a small chemical arm. It latches onto albumin, a protein already in your blood. Riding on albumin shields it from breakdown, and its measured half-life in healthy adults ran about six to eight days. The version without DAC has no albumin anchor, so it clears fast like natural GHRH. Either way, GH rises in pulses, and IGF-1 follows.
How is CJC-1295 supplied?
Injectable (subcutaneous)
What are the side effects of CJC-1295?
| Effect | How serious | What to watch |
|---|---|---|
| No human safety trial has ever been published on CJC-1295 without DAC, the modified GRF 1-29 form. Its risks in people are unmeasured. | Unknown | Nothing useful can be recommended, because there is no human record to draw on. |
| In the two placebo controlled trials of CJC-1295 with DAC, no serious adverse reactions were reported.[1] | None serious reported | Nothing specific, but note the trials were small and ran for weeks, not years. |
| Across growth hormone axis peptides, clinicians report fluid retention, muscle and joint pain, injection site reactions and blood sugar problems.[5] | Mild to moderate, not measured in a trial | Swelling in hands and ankles, joint and muscle pain, blood sugar, injection sites. |
| Powders seized by customs and sold as modified GRF 1-29 turned out to be altered peptides carrying an extra amino acid.[6] | Unknown | You cannot tell by looking. Grey market vials are often not the molecule on the label. |
| Reviewers warn that the unregulated supply chain adds contamination and mislabelling on top of cardiovascular and metabolic risks.[7] | Potentially serious, poorly defined | Blood pressure, blood sugar and blood lipids, discussed with a doctor. |
Is CJC-1295 legal in 2026?
Checked on 6 August 2026. CJC-1295 is not an approved medicine in the United States. Pharmacies nominated it for compounding, and FDA placed it among substances that may present significant safety risks. The nominators later withdrew it, and FDA still lists CJC-1295 in that withdrawn group. FDA writes that it has identified serious adverse events associated with CJC-1295. Those include increased heart rate and a systemic vasodilatory reaction. FDA adds that available clinical data are limited. Growth hormone releasing hormones are also prohibited in sport by WADA.
Status checked against the primary source.
What should CJC-1295 cost?
Most sellers stock CJC-1295 in 5mg vials. Across 15 sellers, those vials run $30.80 to $52.00. Across every vial size, the middle price is $7.00 per mg.
That is a wide spread for one product. Vial size explains part of it, because bigger vials cost less per mg. Testing explains more. A seller who pays a lab to check each batch charges more than one who skips it. Shipping, storage and how much stock is left move the rest.
A price well under that range is a question, not a bargain. The vial may hold less peptide than the label claims. Peptides also break down in heat, so cheap stock can be old stock. Ask to see a certificate of analysis, a lab report on that exact batch, before you buy.
Prices as of 12 October 2026, across 15 sellers of 5mg vials. The two figures are the 10th and 90th percentile. Some sellers charge less, and some charge more.
Where to buy CJC-1295
Running CJC-1295 in your next protocol cycle?
Check out our recommended sources list to find vetted vendors you can trust.
View sourcesCJC-1295 research by condition
Deep dives on CJC-1295
- Best Peptides for Injury Recovery: What the Evidence ShowsBest peptides for injury recovery, weighed on the evidence: what BPC-157, TB-500, GHK-Cu and four others were studied in, plus FDA's legal record in 2026.
- Thymosin Alpha 1 Peptide: Benefits, Dosage and SafetyThymosin alpha 1 peptide explained: how it works, what the trials found, the doses they used, its side effects, and where it stands with the FDA in 2026.
- BPC-157 and TB-500: What the Wolverine Stack Research ShowsBPC-157 and TB-500 (Wolverine stack): no study tested the pair. See the doses the FDA reports from human studies, what was tried together and the safety record.
- How to Reconstitute Peptides: Diluents, Maths and StorageHow to reconstitute peptides, from primary sources: the diluents an FDA label names, the concentration maths, what damages a peptide, and storage figures.
- Best Peptides for Men Over 40: Recovery and LongevityThe best peptides for men over 40: what BPC-157, TB-500, CJC-1295, ipamorelin, Semax and GHK-Cu each do, the reported doses, and how strong the evidence is.
- BPC-157 vs TB-500 Comparison: What the Research ShowsBPC-157 vs TB-500 comparison: what each healing peptide does, what the rat, lab-dish and eye studies found, and why neither has a human injury trial yet.
- BPC-157 Oral vs Injectable: What the Evidence ShowsBPC-157 oral vs injectable, checked against primary sources: no human study compares them, FDA found no human absorption data, and what rat studies show.
- BPC-157 Dosage: What Human and Animal Studies Actually UsedBPC-157 dosage, checked against primary sources: the doses used in human reports and planned in a Phase I trial, animal doses per kg, and FDA and WADA status.
- FDA Compounding Regulations Peptides Users Must KnowFDA compounding regulations peptides users face in 2026: what the July advisory vote and Category 2 removal mean for 503A pharmacies. No peptide is listed yet.
- BPC-157 and TB-500 Post-Surgery Recovery: What Is KnownBPC-157 and TB-500 post surgery recovery: what rodent (rat) and cell studies show, why no human trial sets a start time or dose, the risks and FDA's record.
- CJC-1295 Complete Guide: Mechanism, Trial Doses and SafetyCJC-1295 raised GH 2- to 10-fold in healthy adults, but the 6-to-14-day window is oversold. The honest read on mechanism, DAC vs no-DAC, trial doses and safety.
- 6 Best Peptides for Anti-Ageing and Longevity (2026)The best peptides for anti-ageing and longevity, graded by human evidence: thymosin alpha-1 has the most, while epitalon and MOTS-c have little or none.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
Does CJC-1295 actually build muscle or burn fat?
Is CJC-1295 legal to buy or to prescribe in the United States?
Is CJC-1295 the same thing as growth hormone?
What are the known risks of CJC-1295?
Will CJC-1295 show up on a drug test?
References
- 1.Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism. PMID: 16352683. DOI: 10.1210/jc.2005-1536.
- 2.Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism. PMID: 17018654. DOI: 10.1210/jc.2006-1702.
- 3.Jette L, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. PMID: 15817669. DOI: 10.1210/en.2004-1286.
- 4.Mayfield CK, et al. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. PMID: 41476424. DOI: 10.1177/03635465251357593.
- 5.Dominikowski A, et al. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology. PMID: 42395176. DOI: 10.3389/fendo.2026.1822475.
- 6.Gajda PM, et al. (2019). Glycine-modified growth hormone secretagogues identified in seized doping material. Drug testing and analysis. PMID: 30136411. DOI: 10.1002/dta.2489.
- 7.Coutinho LFD, et al. (2026). A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. PMID: 41880199. DOI: 10.23736/S0022-4707.26.17773-1.
- 8.Knoop A, et al. (2016). Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and bioanalytical chemistry. PMID: 26879649. DOI: 10.1007/s00216-016-9377-3.
This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice.
